{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhang YQ"],"funding":["Fund Program for the Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province","National Natural Science Foundation of China"],"pagination":["429"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9664773"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(1)"],"pubmed_abstract":["<h4>Background</h4>C1q/TNF-related protein 9 (CTRP9) and adiponectin (APN) have beneficial metabolic regulatory and vasoprotective effects. This study explored alteration of CTRP9 and APN multimers during onset of ischemic stroke and development, to provide novel clinical and experimental basis for recognition and prevention of ischemic stroke.<h4>Methods</h4>There were 269 patients with ischemic stroke and 182 control subjects included in this study. Serum levels of CTRP9 and APN multimers in different disease stages were measured.<h4>Results</h4>Serum CTRP9, total APN (tAPN), and high-molecular weight (HMW) APN decreased gradually in stage I (acute stage, within 72 h of onset) of ischemic stroke and increased during stage III (11th day to one month) and stage IV (1 month after), compared"],"journal":["BMC neurology"],"pubmed_title":["Serum CTRP9 and high-molecular weight adiponectin are associated with ischemic stroke."],"pmcid":["PMC9664773"],"funding_grant_id":["81270401","81700327","2018-1059","81470413","82070263"],"pubmed_authors":["Wang XM","Li C","Dai JL","Wang WQ","Zhang YW","Zhang HF","Lau WB","Zhang YQ","Liu XG","Li R"],"additional_accession":[]},"is_claimable":false,"name":"Serum CTRP9 and high-molecular weight adiponectin are associated with ischemic stroke.","description":"<h4>Background</h4>C1q/TNF-related protein 9 (CTRP9) and adiponectin (APN) have beneficial metabolic regulatory and vasoprotective effects. This study explored alteration of CTRP9 and APN multimers during onset of ischemic stroke and development, to provide novel clinical and experimental basis for recognition and prevention of ischemic stroke.<h4>Methods</h4>There were 269 patients with ischemic stroke and 182 control subjects included in this study. Serum levels of CTRP9 and APN multimers in different disease stages were measured.<h4>Results</h4>Serum CTRP9, total APN (tAPN), and high-molecular weight (HMW) APN decreased gradually in stage I (acute stage, within 72 h of onset) of ischemic stroke and increased during stage III (11th day to one month) and stage IV (1 month after), compared","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-19T13:23:11.132Z","creation":"2025-04-19T13:23:11.132Z"},"accession":"S-EPMC9664773","cross_references":{"pubmed":["36380279"],"doi":["10.1186/s12883-022-02967-w"]}}